Table 2 Characteristics of patients in the G3S and IPC cohorts, proportion of eligible patients for TARGIT E and RIOP trials

Age

70–79

1213 (86%)

488 (82.4%)

<0.05

≥80

198 (14%)

104 (17.6%)

pN

pN0

1113 (78.9%)

407 (76%)

0.05

pN1

297 (21.1%)

143 (24%)

Tumor type

Ductal

1064 (75.4%)

515 (87%)

<0.0001

Lobular

177 (12.5%)

67 (11.3%)

Mixed

28 (2%)

9 (1.5%)

Other

137 (9.7%)

1 (0.2%)

Tumor size

≤20 mm

1186 (84.6%)

402 (51.4%)

<0.0001

>20 mm

216 (15.4%)

380 (48.6%)

Grade

1

473 (33.9%)

196 (67.9%)

<0.02

2

718 (51.5%)

271 (47.3%)

3

185 (13.3%)

106 (18.5%)

unknown

18 (1.3%)

19 (3.3%)

Lymphovascular invasion

Yes

150 (13%)

154 (27.8%)

<0.0001

No

1004 (87%)

399 (67.4%)

Hormonal receptor

positive

1243 (90.5%)

405 (69%)

<0.0001

negative

131 (9.5%)

182 (31%)

Local recurrences

Yes

17 (1.2%)

18 (3%)

<0.01

no

1394 (98.8%)

574 (97%)

Eligible patients RIOP (RE)

Yes

499 (36.8%)

114 (19.3%)

<0.0001

no

856 (63.2%)

478 (80.7%)

Eligible patients TARGIT E (TE)

Yes

859 (60.9%)

268 (45.3%)

<0.0001

no

552 (39.1%)

324 (54.7%)